SCHEMBL15760554

SCHEMBL15760554

Cc1ccc2[nH]c3c(c2c1)/C(=C/O)CCC3

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.43
ALDH1A1 P00352 4/20 0.43
LMNA P02545 4/20 0.43
HPGD P15428 3/20 0.43
PTGES O14684 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
MAPT P10636 1/20 0.41
BAZ2B Q9UIF8 1/20 0.40
HSD17B10 Q99714 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
HTT P42858 1/20 0.39
GFER P55789 1/20 0.39
PARP1 P09874 1/20 0.38
ACHE P22303 3/20 0.38
GRIN1 Q05586 3/20 0.38
GRIN2A Q12879 3/20 0.38
GRIN2D O15399 2/20 0.38
GRIN3B O60391 2/20 0.38
GRIN2B Q13224 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2303878 0.78 ALDH1A1 (0.60) KDM4EALDH1A1LMNAHPGDPTGES
SCHEMBL2298349 0.77 PTGES (0.51) KDM4EALDH1A1LMNAHPGDPTGES
SCHEMBL2298348 0.77 PTGES (0.51) KDM4EALDH1A1LMNAHPGDPTGES
SCHEMBL1869103 0.73 MAPT (0.65) KDM4EALDH1A1LMNAHPGDPTGES
SCHEMBL10154875 0.71 KDR (0.70) KDM4EALDH1A1LMNAHPGDL3MBTL1
SCHEMBL2515756 0.70 MAPT (0.60) KDM4EALDH1A1LMNAHPGDPTGES
SCHEMBL6488296 0.70 PTGES (0.43) KDM4EALDH1A1LMNAHPGDPTGES
SCHEMBL6488300 0.70 PTGES (0.43) KDM4EALDH1A1LMNAHPGDPTGES
Hydrochloric Acid SCHEMBL7553962 0.68 ALDH1A1 (0.48) KDM4EALDH1A1LMNAHPGDL3MBTL1
SCHEMBL27352303 0.67 KDM4E (0.46) KDM4EALDH1A1LMNAHPGDPTGES

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140155384-A1 COMPOUNDS AND METHODS OF TREATING DIABETES MEDIVATION TECHNOLOGIES, INC. (US) 2014-06-05 US disclosed
US-20140155384-A1 COMPOUNDS AND METHODS OF TREATING DIABETES MEDIVATION TECHNOLOGIES, INC. (US) 2014-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140155384-A1 COMPOUNDS AND METHODS OF TREATING DIABETES ADRB2, ADRA2C, ADRA2B KDM4E 2441/4885ALDH1A1 1360/4885LMNA 3858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.